These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 20061146)

  • 1. The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
    Isabel E; Bateman KP; Chauret N; Cromlish W; Desmarais S; Duong LT; Falgueyret JP; Gauthier JY; Lamontagne S; Lau CK; Léger S; LeRiche T; Lévesque JF; Li CS; Massé F; McKay DJ; Mellon C; Nicoll-Griffith DA; Oballa RM; Percival MD; Riendeau D; Robichaud J; Rodan GA; Rodan SB; Seto C; Thérien M; Truong VL; Wesolowski G; Young RN; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2010 Feb; 20(3):887-92. PubMed ID: 20061146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.
    Barrett DG; Catalano JG; Deaton DN; Long ST; McFadyen RB; Miller AB; Miller LR; Samano V; Tavares FX; Wells-Knecht KJ; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):22-7. PubMed ID: 17157021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.
    Kassahun K; Black WC; Nicoll-Griffith D; McIntosh I; Chauret N; Day S; Rosenberg E; Koeplinger K
    Drug Metab Dispos; 2011 Jun; 39(6):1079-87. PubMed ID: 21422190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
    Gauthier JY; Chauret N; Cromlish W; Desmarais S; Duong LT; Falgueyret JP; Kimmel DB; Lamontagne S; Léger S; LeRiche T; Li CS; Massé F; McKay DJ; Nicoll-Griffith DA; Oballa RM; Palmer JT; Percival MD; Riendeau D; Robichaud J; Rodan GA; Rodan SB; Seto C; Thérien M; Truong VL; Venuti MC; Wesolowski G; Young RN; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2008 Feb; 18(3):923-8. PubMed ID: 18226527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.
    Isabel E; Mellon C; Boyd MJ; Chauret N; Deschênes D; Desmarais S; Falgueyret JP; Gauthier JY; Khougaz K; Lau CK; Léger S; Levorse DA; Li CS; Massé F; Percival MD; Roy B; Scheigetz J; Thérien M; Truong VL; Wesolowski G; Young RN; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2011 Feb; 21(3):920-3. PubMed ID: 21232956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors.
    Rankovic Z; Cai J; Kerr J; Fradera X; Robinson J; Mistry A; Hamilton E; McGarry G; Andrews F; Caulfield W; Cumming I; Dempster M; Waller J; Scullion P; Martin I; Mitchell A; Long C; Baugh M; Westwood P; Kinghorn E; Bruin J; Hamilton W; Uitdehaag J; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1524-7. PubMed ID: 20149657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis.
    Ma B; Luo B; Euler DH; Cusick TE; Wesolowski G; Glantschnig H; Duong LT; Ou Y; Carroll SS; Lubbers LS
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Apr; 390(4):435-441. PubMed ID: 28220210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans.
    Kassahun K; McIntosh I; Koeplinger K; Sun L; Talaty JE; Miller DL; Dixon R; Zajic S; Stoch SA
    Drug Metab Dispos; 2014 May; 42(5):818-27. PubMed ID: 24553380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold.
    Teno N; Masuya K
    Curr Top Med Chem; 2010; 10(7):752-66. PubMed ID: 20337583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the discovery of cathepsin K inhibitors on bone resorption.
    Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain.
    Irie O; Kosaka T; Ehara T; Yokokawa F; Kanazawa T; Hirao H; Iwasaki A; Sakaki J; Teno N; Hitomi Y; Iwasaki G; Fukaya H; Nonomura K; Tanabe K; Koizumi S; Uchiyama N; Bevan SJ; Malcangio M; Gentry C; Fox AJ; Yaqoob M; Culshaw AJ; Allan Hallett
    J Med Chem; 2008 Sep; 51(18):5502-5. PubMed ID: 18754655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidomimetic inhibitors of cathepsin K.
    Black WC
    Curr Top Med Chem; 2010; 10(7):745-51. PubMed ID: 20337585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
    Robichaud J; Black WC; Thérien M; Paquet J; Oballa RM; Bayly CI; McKay DJ; Wang Q; Isabel E; Léger S; Mellon C; Kimmel DB; Wesolowski G; Percival MD; Massé F; Desmarais S; Falgueyret JP; Crane SN
    J Med Chem; 2008 Oct; 51(20):6410-20. PubMed ID: 18811135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
    Nicoll-Griffith DA
    Expert Opin Drug Discov; 2012 Apr; 7(4):353-66. PubMed ID: 22458506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a potent and selective non-basic cathepsin K inhibitor.
    Li CS; Deschenes D; Desmarais S; Falgueyret JP; Gauthier JY; Kimmel DB; Léger S; Massé F; McGrath ME; McKay DJ; Percival MD; Riendeau D; Rodan SB; Thérien M; Truong VL; Wesolowski G; Zamboni R; Black WC
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1985-9. PubMed ID: 16413777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
    Lindström E; Rizoska B; Henderson I; Terelius Y; Jerling M; Edenius C; Grabowska U
    J Transl Med; 2018 May; 16(1):125. PubMed ID: 29743078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors that influence oral bioavailability; a cathepsin K inhibitor for human studies.
    Veber DF
    Adv Exp Med Biol; 2009; 611():607-10. PubMed ID: 19400330
    [No Abstract]   [Full Text] [Related]  

  • 19. Dioxo-triazines as a novel series of cathepsin K inhibitors.
    Rankovic Z; Cai J; Fradera X; Dempster M; Mistry A; Mitchell A; Long C; Hamilton E; King A; Boucharens S; Jamieson C; Gillespie J; Cumming I; Uitdehaag J; van Zeeland M
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1488-90. PubMed ID: 20153187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.
    Barrett DG; Boncek VM; Catalano JG; Deaton DN; Hassell AM; Jurgensen CH; Long ST; McFadyen RB; Miller AB; Miller LR; Payne JA; Ray JA; Samano V; Shewchuk LM; Tavares FX; Wells-Knecht KJ; Willard DH; Wright LL; Zhou HQ
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3540-6. PubMed ID: 15982880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.